Pfizer Beats Q3 Estimates and Raises 2026 Outlook on Eliquis and Cancer Drugs; Names New CFO
Pfizer reported adjusted Q3 profit of 87 cents a share on $16.58 billion in revenue, both above forecasts, and lifted its full-year guidance as newer drugs offset falling Covid sales.